The latest treatment options for bladder cancer
- 29 October 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 128 (1), 85-95
- https://doi.org/10.1093/bmb/ldy034
Abstract
Introduction: Bladder cancer carries a high healthcare burden and a poor prognosis once distant metastatic spread has occurred. Sources of data: We utilised a PubMed/MEDLINE literature search using the terms bladder cancer, chemotherapy, immunotherapy, intra-vesical therapy, surgery and radiotherapy, and current clinical management guidelines (Association of Cancer Physicians, British Association of Urological Surgeons, National Institute for Health and Care Excellence, European Association of Urology). Areas of agreement: Optimal bladder cancer management requires a multi-modal approach incorporating surgery, radiotherapy, chemotherapy and immunotherapy. Areas of controversy: Selection criteria for radical surgery, or radiotherapy as a bladder sparing option, and their relative efficacy, remains poorly defined. Growing points: Palliative immunotherapy has been recently established for advanced bladder cancer after prior chemotherapy. Earlier use is under investigation. Areas timely for developing research: Validated predictive biomarkers, potentially from easily repeatable sites ('liquid biopsies'), will be required to optimise use of molecularly targeted treatment options.Keywords
This publication has 53 references indexed in Scilit:
- Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence CystoscopyJournal of Urology, 2012
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Orthotopic Neobladder versus Ileal Conduit Urinary Diversion after Cystectomy – A Quality-of-Life Based ComparisonThe Annals of The Royal College of Surgeons of England, 2009
- A re‐staging transurethral resection predicts early progression of superficial bladder cancerBJU International, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis CollaborationEuropean Urology, 2005
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerThe New England Journal of Medicine, 2003